Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus

被引：0
|
作者：
Lazarus, Mark [1 ]
Newcombe, Paul [1 ]
Furie, Richard A. [2 ]
Brohawn, Philip [3 ]
White, Wendy [3 ]
Sinibaldi, Dominic [3 ]
Ferrari, Nicola [1 ]
Tummala, Raj [3 ]
Al-Mossawi, Hussein [1 ]
Vital, Edward [4 ]
Morand, Eric F. [5 ]
Muthas, Daniel [6 ]
Ramaswamy, Madhu [3 ]
机构：
[1] AstraZeneca, Cambridge, England
[2] Northwell Hlth, Great Neck, NY USA
[3] AstraZeneca, Gaithersburg, MD USA
[4] Univ Leeds, Leeds, England
[5] Monash Univ, Melbourne, Australia
[6] AstraZeneca, Gothenburg, Sweden
来源：
ARTHRITIS & RHEUMATOLOGY | 2022年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0360
引用
收藏
页码：714 / 715
页数：2
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF ANIFROLUMAB IN PATIENTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF THE SECOND PHASE 3 RANDOMIZED CONTROLLED TRIAL
    Morand, Eric F.
    Furie, Richard
    Tanaka, Yoshiya
    Bruce, Ian N.
    Askanase, Anca D.
    Richez, Christophe
    Bae, Sang-Cheol
    Brohawn, Mr Philip Z.
    Pineda, Lilia
    Berglind, Anna
    Tummala, Raj
    [J]. INTERNAL MEDICINE JOURNAL, 2020, 50 : 22 - 23
  • [2] Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial
    Morand, Eric
    Furie, Richard
    Tanaka, Yoshiya
    Bruce, Ian
    Askanase, Anca
    Riche'z, Christophe
    Bae, Sang-Cheol
    Brohawn, Philip
    Pineda, Lilia
    Berglind, Anna
    Tummala, Raj
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [3] A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus
    Furie, Richard
    Morand, Eric
    Bruce, Ian
    Manzi, Susan
    Kalunian, Kenneth
    Vital, Edward
    Lawrence-Ford, Theresa
    Gupta, Ramesh
    Hiepe, Falk
    Santiago, Mittermayer
    Brohawn, Philip
    Berglind, Anna
    Tummala, Raj
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [4] Evaluation of the Efficacy and Safety of Anifrolumab in Moderate-to-Severe Systemic Lupus Erythematosus
    Cingireddy, Ananya Reddy
    Ramini, Navya
    Cingireddy, Anirudh Reddy
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [5] Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
    Chia, Yen Lin
    Tummala, Raj
    Mai, Tu H.
    Rouse, Tomas
    Streicher, Katie
    White, Wendy, I
    Morand, Eric F.
    Furie, Richard A.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (09): : 1094 - 1105
  • [6] Anifrolumab Differentially Suppresses Peripheral Biomarkers of Systemic Lupus Erythematosus Compared with Placebo in a Phase IIb Trial
    Guo, Xiang
    Wang, L.
    Illei, G.
    Brohawn, P.
    Higgs, Brandon
    White, Wendy
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [7] Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
    Clowse, Megan E. B.
    Wallace, Daniel J.
    Furie, Richard
    Petri, Michelle
    Pike, Marilyn
    Leszczynski, Piotr
    Neuwelt, C. Michael
    Hobbs, Kathryn
    Keiserman, Mauro
    Duca, Liliana
    Kalunian, Kenneth
    Bongardt, Sabine
    Stach, Christian
    Beaudot, Carolyn
    Kilgallen, Brian
    Galateanu, Catrinel
    Gordon, Caroline
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [8] EFFICACY OF ANIFROLUMAB IN ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: PATIENT SUBGROUP ANALYSIS OF BICLA RESPONSE IN 2 PHASE 3 TRIALS
    Morand, E. F.
    Furie, R.
    Tanaka, Y.
    Kalyani, R.
    Abreu, G.
    Pineda, L.
    Tummala, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 32 - 32
  • [9] Phase 3 Trial Results with Blisibimod, a Selective Inhibitor of B-Cell Activating Factor, in Subjects with Moderate-to-Severe Systemic Lupus Erythematosus
    Merrill, Joan T.
    Martin, Renee S.
    Shanahan, William
    Scheinberg, Morton
    Kalunian, Kenneth C.
    Wofsy, David
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [10] Target Modulation of a Type I Interferon Gene Signature and Pharmacokinetics of Anifrolumab in a Phase IIb Study of Patients with Moderate to Severe Systemic Lupus Erythematosus
    Brohawn, Philip
    Santiago, Lingning
    Morehouse, Chris
    Higgs, Brandon
    Illei, Gabor
    Ranade, Koustubh
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
12345